---
title: "NUTRIBAND INC C/WTS (TO PUR COM) | 10-K: FY2025 Revenue: USD 2.14 M"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/237925477.md"
datetime: "2025-04-28T21:22:57.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/237925477.md)
  - [en](https://longbridge.com/en/news/237925477.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/237925477.md)
generator: "portal-rs"
---

# NUTRIBAND INC C/WTS (TO PUR COM) | 10-K: FY2025 Revenue: USD 2.14 M

Revenue: As of FY2025, the actual value is USD 2.14 M.

EPS: As of FY2025, the actual value is USD -0.99.

EBIT: As of FY2025, the actual value is USD -10.28 M.

### Segment Revenue

-   **Pocono Pharmaceuticals**: Revenue for the year ending January 31, 2025, was $2,139,537, compared to $1,920,280 for the year ending January 31, 2024.
-   **4P Therapeutics**: No revenue was generated for the year ending January 31, 2025, compared to $165,034 for the year ending January 31, 2024.

### Operational Metrics

-   **Gross Profit**: Pocono Pharmaceuticals reported a gross profit of $743,317 for the year ending January 31, 2025, compared to $744,391 for the year ending January 31, 2024.
-   **Selling, General and Administrative Expenses**: Pocono Pharmaceuticals incurred $661,805 in expenses for the year ending January 31, 2025, compared to $606,275 for the year ending January 31, 2024.
-   **Research and Development**: 4P Therapeutics incurred $3,119,134 in research and development expenses for the year ending January 31, 2025, compared to $1,960,425 for the year ending January 31, 2024.

### Cash Flow

-   **Operating Cash Flow**: The company used cash of - $4,626,564 in operations for the year ending January 31, 2025.
-   **Investing Cash Flow**: Cash used in investing activities was - $92,043 for the year ending January 31, 2025.
-   **Financing Cash Flow**: Cash provided by financing activities was $8,537,384 for the year ending January 31, 2025.

### Unique Metrics

-   **Impairment Charge**: The company recorded an impairment charge of $3,595,216 for the year ending January 31, 2025, reducing the value of its goodwill and intangible assets.

### Outlook / Guidance

-   The company plans to continue the development of its AVERSA Fentanyl product, with an estimated budget of $3.2 million through NDA submission following an amended agreement with Kindeva Drug Delivery.

### Related Stocks

- [NTRBW.US](https://longbridge.com/en/quote/NTRBW.US.md)

## Related News & Research

- [BMO Says 'Sell' Nike Stock. What's Behind the Bearish Outlook on NKE and LULU?](https://longbridge.com/en/news/298451729.md)
- [Memory Is the New ‘King’ of Chips, Taking Over 50% of Semiconductor Revenue, Susquehanna Says](https://longbridge.com/en/news/298476095.md)
- [Broadcom (AVGO) Is Storming the AI Market. I'm Bullish](https://longbridge.com/en/news/298457941.md)
- [Super Micro Computer, Inc. $SMCI Position Increased by TD Waterhouse Canada Inc.](https://longbridge.com/en/news/298428833.md)
- [91,654 Shares in Fortuna Mining Corp. $FSM Purchased by TD Waterhouse Canada Inc.](https://longbridge.com/en/news/298426725.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**